Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma
驱动皮肤T细胞淋巴瘤的靶向表观遗传机制
基本信息
- 批准号:10800864
- 负责人:
- 金额:$ 38.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-02 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AT Rich SequenceAblationAmerican Cancer SocietyAutomobile DrivingBinding ProteinsBiologicalBloodCD4 Positive T LymphocytesCancer CenterChromatinClinicClinicalClinical InvestigatorCollectionCutaneous T-cell lymphomaDeacetylationDeletion MutationDermatologyDiagnosisDiseaseDown-RegulationDrug CombinationsEpigenetic ProcessEtiologyFunctional disorderGPR2 geneGenetic TranscriptionGenomicsGoalsGrowth and Development functionHematologistHematologyHistone DeacetylaseHistone DeacetylationHomingHumanImmunologistInterventionLymphocyteLymphoma cellLysineMalignant - descriptorMature T-LymphocyteMethyltransferaseMolecularOncogenicOrganOutcomePathogenesisPathogenicityPatientsPeripheralPhosphorylationPoint MutationRare DiseasesRepressionRoleSamplingSchemeSezary SyndromeSezary cellSignal TransductionSkinSmall-Cell LymphomaSpecimenStat5 proteinSurvival RateT-Cell DevelopmentT-Cell LymphomaT-LymphocyteTestingTherapeuticThymus GlandTumor Suppressor ProteinsWorkchemokine receptorclinical translationcytokinederepressiondesigneffective interventioneffective therapyepigenetic drugepigenetic silencinghistone methylationinhibitorinsightleukemialymph nodesmalignant phenotypemouse modelnotch proteinnoveloverexpressionpalliativepreventprogramspromotertranscription factor
项目摘要
ABSTRACT
The lack of a clear understanding of the pathophysiology of Cutaneous T cell Lymphoma
(CTCL) and in particular its aggressive leukemic form Sézary Syndrome, has impeded
therapeutic advances, and current treatments are only palliative. Although CTCL is a relatively
rare disease, Moffitt Cancer Center Malignant Hematology and USF Dermatology Departments
manages about 100 new patients with CTCL annually. This study represents a concerted effort
by a team of clinical investigators and translational immunologists at Moffitt to identify new
effective treatments for CTCL patients with aggressive disease, based on the discovery of key
molecular regulators of Sézary Syndrome development and growth. Specifically, our new
mouse models indicate that Special AT-rich region binding protein 1 (SATB1), a master
genomic organizer and a key regulator of T-cell development and maturation, prevents mature T
cell malignization by repressing crucial pathogenic drivers of Sézary cells. Our central
hypothesis is that SATB1 acts as a tumor suppressor in CTCL, by repressing STAT5 activation,
chemokine receptors that govern T cell homing to the skin and transcription factors commonly
de-regulated in malignant T cells. Accordingly, restoring SATB1 expression by targeting histone
methylation and de-acetylation will avert the malignant phenotype of Sézary cells. We will
leverage a growing collection of aphaeresis specimens and unique mouse models to dissect the
epigenetic mechanisms governing the pathogenesis of Sézary Syndrome, with the overarching
goal of subsequently targeting them through more effective interventions in our clinic.
In Aim 1, we will elucidate how SATB1 silencing drives the pathogenesis of CTCL. Based on
our preliminary results, our hypothesis is that Satb1 silencing cooperates with Notch signaling to
elicit a STAT5-, CCR10-, IKZF2/HELIOS-dependent transcriptional program leading to the
progressive expansion, skin homing and malignant transformation of post-thymic CD4 T cells.
In Aim 2, we will define the complementary mechanisms leading to epigenetic silencing of
the SATB1 locus in Sézary Syndrome. We will test the hypothesis that SATB1 is silenced in
Sézary cells through a combination of histone methylation at K27 and K9 that, along with and
lysine de-acetylation, resulting in significant changes in chromatin accessibility.
In Aim 3, we will leverage our new biological understanding to identify the combination of
epigenetic drugs that more effectively restore SATB1 expression and thwart oncogenic signals
in Sézary cells.
Our work will exert a profound effect in the field by elucidating how epigenetic repression of
the master genomic organizer SATB1 governs the malignant transformation of mature CD4 T
cells in coordination with NOTCH signaling, leading to fatal skin accumulation of lymphocytes in
Sézary patients. This mechanistic insight will inform the most effective combination of drugs
needed to de-repress the SATB1 locus and antagonize oncogenic signals, which will overturn
malignant Sézary cells. This biological understanding will be followed by clinical interventions at
Moffitt for patients with aggressive CTCL, including Sézary Syndrome.
摘要
对皮肤T细胞淋巴瘤的病理生理学缺乏明确的认识
(CTCL),特别是其侵袭性白血病形式Sézary综合征,阻碍了
治疗进展,而目前的治疗方法只是治标不治本。虽然CTCL是一个相对
罕见疾病,莫菲特癌症中心恶性血液病和USF皮肤科
每年管理约100名新的CTCL患者。这项研究表明,
由莫菲特的临床研究人员和翻译免疫学家组成的团队,
根据对CTCL患者侵袭性疾病的关键发现,
Sézary综合征发育和生长的分子调节剂。具体来说,我们的新
小鼠模型表明,特异性AT富集区结合蛋白1(SATB 1),
基因组组织者和T细胞发育和成熟的关键调节因子,阻止成熟的T细胞
通过抑制Sézary细胞的关键致病驱动因素来抑制细胞增殖。我们的中央
假设SATB 1通过抑制STAT 5活化,
趋化因子受体控制T细胞归巢到皮肤和转录因子通常
在恶性T细胞中失调。因此,通过靶向组蛋白来恢复SATB 1表达,
甲基化和去乙酰化将避免Sézary细胞的恶性表型。我们将
利用越来越多的单采标本和独特的小鼠模型来解剖
Sézary综合征发病机制的表观遗传机制,
我们的目标是随后通过在我们的诊所更有效的干预措施来针对他们。
在目标1中,我们将阐明SATB 1沉默如何驱动CTCL的发病机制。基于
根据我们的初步结果,我们的假设是Satb 1沉默与Notch信号传导合作,
引发STAT 5-、CCR 10-、IKZF 2/HELIOS依赖性转录程序,导致
胸腺后CD 4 T细胞的进行性扩增、皮肤归巢和恶性转化。
在目标2中,我们将定义导致表观遗传沉默的互补机制,
Sézary综合征中的SATB 1位点。我们将测试SATB 1在以下情况下沉默的假设:
Sézary细胞通过K27和K9的组蛋白甲基化的组合,沿着和
赖氨酸去乙酰化,导致染色质可及性的显著变化。
在目标3中,我们将利用我们新的生物学理解来确定以下组合:
更有效地恢复SATB 1表达并阻断致癌信号的表观遗传药物
塞扎里监狱
我们的工作将发挥深远的影响,在该领域阐明如何表观遗传抑制的
主基因组组织者SATB 1控制成熟CD 4 T细胞的恶性转化,
细胞与NOTCH信号协调,导致淋巴细胞在皮肤中的致命积累。
塞扎里的病人这种机制的见解将告知最有效的药物组合
需要去抑制SATB 1位点并拮抗致癌信号,这将推翻
恶性Sézary细胞这一生物学理解将随后进行临床干预,
Moffitt用于侵袭性CTCL患者,包括Sézary综合征。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jose R Conejo-Garcia其他文献
Jose R Conejo-Garcia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jose R Conejo-Garcia', 18)}}的其他基金
OR2H1 is an effective target for CAR T cells in human epithelial tumors
OR2H1是人类上皮肿瘤中CAR T细胞的有效靶点
- 批准号:
10563356 - 财政年份:2023
- 资助金额:
$ 38.8万 - 项目类别:
Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma
驱动皮肤T细胞淋巴瘤的靶向表观遗传机制
- 批准号:
10204969 - 财政年份:2019
- 资助金额:
$ 38.8万 - 项目类别:
Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma
驱动皮肤T细胞淋巴瘤的靶向表观遗传机制
- 批准号:
10441410 - 财政年份:2019
- 资助金额:
$ 38.8万 - 项目类别:
Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma
驱动皮肤T细胞淋巴瘤的靶向表观遗传机制
- 批准号:
9797573 - 财政年份:2019
- 资助金额:
$ 38.8万 - 项目类别:
B cell-dependent anti-tumor immunity in ovarian cancer
卵巢癌中 B 细胞依赖性抗肿瘤免疫
- 批准号:
9789207 - 财政年份:2018
- 资助金额:
$ 38.8万 - 项目类别:
B cell-dependent anti-tumor immunity in ovarian cancer
卵巢癌中 B 细胞依赖性抗肿瘤免疫
- 批准号:
10231230 - 财政年份:2018
- 资助金额:
$ 38.8万 - 项目类别:
B cell-dependent anti-tumor immunity in ovarian cancer
卵巢癌中 B 细胞依赖性抗肿瘤免疫
- 批准号:
10477986 - 财政年份:2018
- 资助金额:
$ 38.8万 - 项目类别:
B cell-dependent anti-tumor immunity in ovarian cancer
卵巢癌中 B 细胞依赖性抗肿瘤免疫
- 批准号:
10801106 - 财政年份:2018
- 资助金额:
$ 38.8万 - 项目类别:
Rapid Exoproteome Antigen Profiling of antibodies produced in the ovarian cancer microenvironment
卵巢癌微环境中产生的抗体的快速外蛋白组抗原分析
- 批准号:
10286353 - 财政年份:2018
- 资助金额:
$ 38.8万 - 项目类别:
Effects of Common Polymorphisms in Immune Sensors in Tumor Immunosurveillance
免疫传感器常见多态性在肿瘤免疫监视中的作用
- 批准号:
9284420 - 财政年份:2017
- 资助金额:
$ 38.8万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 38.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 38.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 38.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 38.8万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 38.8万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 38.8万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 38.8万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 38.8万 - 项目类别:
Continuing Grant
Cryo laser-ablation system (157+193nm) with 'triple-quad' plasma mass spectrometer, Cryo-LA-ICPMS/MS
带有“三重四极杆”等离子体质谱仪、Cryo-LA-ICPMS/MS 的冷冻激光烧蚀系统 (157 193nm)
- 批准号:
515081333 - 财政年份:2023
- 资助金额:
$ 38.8万 - 项目类别:
Major Research Instrumentation
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 38.8万 - 项目类别:
Standard Grant